Oxford BioMedica’s (OXB) LentiVector technology underpins the company’s strategy. OXB generates significant revenue from partners that utilise its technology, notably Novartis, Bioverativ, Orchard Therapeutics and Immune Design. OXB is in partnering discussions about internally developed assets.
Oxford BioMedica (OXB) is a global leader in lentiviral development and manufacturing. Maiden profits last year are evidence of strong operational momentum and ongoing validation of its business model. OXB is expanding its manufacturing facilities, more than doubling its current capacity by 2020 to match the increasing demand and to continue growing its platform revenues. In the near term, revenue will continue to be driven by the Novartis partnership for CAR-T Kymriah as the commercial roll-out continues. OXB has several established development and manufacturing partnerships including Sanofi & Orchard Therapeutics, and is continually looking to spin-out its internally developed assets. Recently, partner Axovant announced positive interim results for AXO-Lenti-PD (in-licensed from OXB) in the ongoing Phase II trial (SUNRISE-PD) which is now enrolling the next dose escalation cohort of patients. As of 31 December, OXB had gross cash of £32.2m. We place our forecasts under review.
Cell- and gene-therapy is the focus of much industry attention as it can dramatically alter the outcomes of many diseases. OXB’s proprietary lentivector platform has demonstrated promise in many indications.